Chargement en cours...
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
BACKGROUND: BRAF inhibitors are effective anticancer agents in BRAF-mutated melanomas. By contrast, evidences about sensitivity of thyroid carcinomas to BRAF inhibition are conflicting and it has been proposed that BRAF V600E thyroid carcinoma cells are less sensitive to BRAF inhibitors due to activ...
Enregistré dans:
| Publié dans: | Cancer Cell Int |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5628448/ https://ncbi.nlm.nih.gov/pubmed/29033690 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-017-0457-z |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|